Coloplast A/S
As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
The programme commenced on 22 February 2021 and is expected to end by 23 August 2021.
The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.
The following transactions have been executed during the period 8 – 12 March 2021:
| Date | Number of shares | Average purchase price, DKK | Transaction value, DKK |
| 08 March 2021 | 300 | 873.04 | 261,912 |
| 09 March 2021 | 250 | 880.19 | 220,048 |
| 10 March 2021 | 300 | 900.08 | 270,024 |
| 11 March 2021 | 400 | 910.37 | 364,148 |
| 12 March 2021 | 400 | 913.66 | 365,464 |
| Accumulated until now under the programme | 56,050 | 908.24 | 50,906,832 |
Henceforth, Coloplast owns 3,091,947 treasury B shares of DKK 1 equal to 1.43% of the company’s total share capital.
An overview showing the transaction data for the period 8 – 12 March 2021 is enclosed.
Kind regards,
Investor Relations
Coloplast A/S
Tel. +45 4911 1800
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.com
Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-03.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bitget Limited26.12.2025 11:00:00 CET | Press release
Bitget Introduces Major App Upgrade, Unifying Crypto, Stocks, Onchain, and TradFi Markets in a Unified Interface for 120 Million Users
Bitget Limited26.12.2025 08:26:00 CET | Press release
Bitget Closes November with $10B+ Stock Futures Volume and 34K BTC Reserves as UEX Momentum Accelerates
Teva Pharmaceutical Industries Ltd24.12.2025 14:36:11 CET | Press release
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
The Magnum Ice Cream Company N.V.24.12.2025 11:52:30 CET | Press release
Director/PDMR Shareholding
Afarak Group SE24.12.2025 10:00:00 CET | Press release
AFARAK GROUP SE: DISTRIBUTION OF ASSETS FROM THE RESERVE FOR INVESTED UNRESTRICTED EQUITY
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
